TriangleDISEASE & TREATMENT SETTING
Soft Tissue Sarcoma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Soft Tissue Sarcoma
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- unresolved
- derivation note
- Derived from NCI topic(s): Soft Tissue Sarcoma. Strongest NCIt resolution: ambiguous. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
9 more-specific settings
VOTRIENT: advanced Soft tissue sarcoma after prior therapy →metastatic Soft Tissue Sarcoma →localized Soft Tissue Sarcoma →advanced Soft Tissue Sarcoma →Stage I Soft Tissue Sarcoma →Stage II Soft Tissue Sarcoma →Stage III advanced Soft Tissue Sarcoma →Stage IV Soft Tissue Sarcoma →recurrent Soft Tissue Sarcoma →
Study evidence for this setting
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Bevacizumab and Radiation Therapy for Sarcomas
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Dalteparin in Preventing DVT in Participants With Cancer
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
Indication-specific source history
2016-10-19 · Lartruvo (olaratumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-soft-tissue-sarcoma
- event id
- fda-5bbe5ac7615f9f31
- event date
- 2016-10-19
- event kind
- accelerated-approval
- drug or regimen
- Lartruvo (olaratumab)
- source indication text
- In combination with doxorubicin for adults with soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery
- match phrase
- soft tissue sarcoma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-0bce2074ec71ddd1ede2
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2020-02-25 · Lartruvo (olaratumab) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-soft-tissue-sarcoma
- event id
- fda-04f1981cb409d228
- event date
- 2020-02-25
- event kind
- withdrawal
- drug or regimen
- Lartruvo (olaratumab)
- source indication text
- In combination with doxorubicin for adults with soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery
- match phrase
- soft tissue sarcoma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-0bce2074ec71ddd1ede2
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-soft-tissue-sarcoma
- binding id
- ncit-C115292
- source collection
- ncit-concept
- source key
- C115292
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-soft-tissue-sarcoma
- binding id
- ncit-C7707
- source collection
- ncit-concept
- source key
- C7707
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-soft-tissue-sarcoma
- binding id
- ncit-C7715
- source collection
- ncit-concept
- source key
- C7715
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-soft-tissue-sarcoma
- binding id
- ncit-C9306
- source collection
- ncit-concept
- source key
- C9306
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice